跳至主要内容
临床试验/NCT02722161
NCT02722161已完成1 期

A Phase I, Open-label, Single-dose Trial to Investigate Metabolism and Pharmacokinetics of [14C]BI 1482694 Administered as Oral Solution in Healthy Male Volunteers

Boehringer Ingelheim1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
1
主要终点
Mass balance recovery of [14C]-radioactivity in urine: fe urine, 0-tz (fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)

研究概览

简要总结

To investigate the basic pharmacokinetics of BI 1482694, its metabolites M1 and M2, and [14C]-radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1482694 given to healthy male volunteers

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

[14C]BI 1482694

Experimental

干预措施: [14C]BI 1482694 (Drug)

结局指标

主要结局

Mass balance recovery of [14C]-radioactivity in urine: fe urine, 0-tz (fraction excreted in urine as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)

时间窗: up to 1181 hours (7 weeks)

Mass balance recovery of [14C]-radioactivity in faeces: fe faeces, 0-tz (fraction excreted in faeces as percentage of the administered dose over the time interval from 0 to the last quantifiable time point)

时间窗: up to 1181 hours (7 weeks)

次要结局

  • AUC0-tz (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point) for BI 1482694 in plasma(up to 72 hours)
  • AUC0-tz (area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point) for [14C]-radioactivity in plasma(up to 336 hours)
  • Cmax (maximum measured concentration of the analyte) for [14C]-radioactivity in plasma(up to 336 hours)
  • Cmax (maximum measured concentration of the analyte) for BI 1482694 in plasma(up to 72 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Olmutinib (BI 1482694) ADME Study | 临床试验